{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:26:35Z","timestamp":1779909995676,"version":"3.53.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10787-021-00905-9","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:04:20Z","timestamp":1642723460000},"page":"61-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pathophysiological basis in the management of myasthenia gravis: a mini review"],"prefix":"10.1007","volume":"30","author":[{"given":"Aiswarya","family":"Binu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarath S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma Devi","family":"Padma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1047-9153","authenticated-orcid":false,"given":"Krishnadas","family":"Madhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"905_CR1","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1016\/0090-1229(89)90083-4","volume":"53","author":"E Arsura","year":"1989","unstructured":"Arsura E (1989) Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 53:S170\u2013S179. https:\/\/doi.org\/10.1016\/0090-1229(89)90083-4","journal-title":"Clin Immunol Immunopathol"},{"key":"905_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mus.880130808","volume":"13","author":"RG Bashuk","year":"1990","unstructured":"Bashuk RG, Krendel DA (1990) Myasthenia gravis presenting as weakness after magnesium administration. Muscle Nerve 13:708\u2013712. https:\/\/doi.org\/10.1002\/mus.880130808","journal-title":"Muscle Nerve"},{"key":"905_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48\u201349","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 48\u201349:143\u2013148. https:\/\/doi.org\/10.1016\/j.jaut.2014.01.003","journal-title":"J Autoimmun"},{"key":"905_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1212\/WNL.32.10.1077","volume":"32","author":"CT Bever","year":"1982","unstructured":"Bever CT, Chang HW, Penn AS, Jaffe IA, Bock E (1982) Penicillamine-induced myasthenia gravis: Effects of penicillamine on acetylcholine receptor. Neurology 32:1077\u20131077. https:\/\/doi.org\/10.1212\/WNL.32.10.1077","journal-title":"Neurology"},{"key":"905_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0003-4975(01)02678-9","volume":"72","author":"JM Budde","year":"2001","unstructured":"Budde JM, Morris CD, Gal AA, Mansour KA, Miller JI (2001) Predictors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg 72:197\u2013202. https:\/\/doi.org\/10.1016\/S0003-4975(01)02678-9","journal-title":"Ann Thorac Surg"},{"key":"905_CR6","first-page":"308","volume":"126","author":"R Cadisch","year":"1996","unstructured":"Cadisch R, Streit E, Hartmann K (1996) Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax). Schweiz Med Wochenschr 126:308\u2013310","journal-title":"Schweiz Med Wochenschr"},{"key":"905_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1046\/j.1526-0968.2000.004004291.x","volume":"4","author":"H Chiu","year":"2000","unstructured":"Chiu H, Chen W, Yeh J (2000) The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 4:291\u2013295. https:\/\/doi.org\/10.1046\/j.1526-0968.2000.004004291.x","journal-title":"Ther Apher"},{"key":"905_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1191\/0961203305LU2118OA","volume":"14","author":"E Ciafaloni","year":"2005","unstructured":"Ciafaloni E (2005) Mycophenolate mofetil and myasthenia gravis. Lupus 14:46\u201349. https:\/\/doi.org\/10.1191\/0961203305LU2118OA","journal-title":"Lupus"},{"key":"905_CR9","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Investig 116:2843\u20132854. https:\/\/doi.org\/10.1172\/JCI29894","journal-title":"J Clin Investig"},{"issue":"3","key":"905_CR100","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JND-190464","volume":"7","author":"S Datta","year":"2020","unstructured":"Datta S, Singh S, Govindarajan R (2020) Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: a case series. J Neuro Dis 7(3):269\u2013277. https:\/\/doi.org\/10.3233\/JND-190464","journal-title":"J Neuro Dis"},{"key":"905_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archneur.1961.00450120077009","volume":"4","author":"AG Engel","year":"1961","unstructured":"Engel AG (1961) Thyroid function and myasthenia gravis. Arch Neurol 4:663\u2013674. https:\/\/doi.org\/10.1001\/archneur.1961.00450120077009","journal-title":"Arch Neurol"},{"key":"905_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1113\/jphysiol.2004.066498","volume":"559","author":"SJ Etherington","year":"2004","unstructured":"Etherington SJ, Everett AW (2004) Postsynaptic production of nitric oxide implicated in long-term depression at the mature amphibian (Bufo marinus) neuromuscular junction: NO-mediated synaptic depression. J Physiol 559:507\u2013517. https:\/\/doi.org\/10.1113\/jphysiol.2004.066498","journal-title":"J Physiol"},{"key":"905_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000116785","volume":"32","author":"A Evoli","year":"1992","unstructured":"Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P (1992) Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 32:37\u201343. https:\/\/doi.org\/10.1159\/000116785","journal-title":"Eur Neurol"},{"issue":"2","key":"905_CR101","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C et al (2018) Treatment of myasthenia gravis. Neuro Clin 36(2):311\u2013337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011","journal-title":"Neuro Clin"},{"key":"905_CR13","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"905_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"905_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.nurt.2008.08.011","volume":"5","author":"R Gold","year":"2008","unstructured":"Gold R, Schneider-Gold C (2008) Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 5:535\u2013541. https:\/\/doi.org\/10.1016\/j.nurt.2008.08.011","journal-title":"Neurotherapeutics"},{"key":"905_CR16","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S3309","author":"C Heatwole","year":"2008","unstructured":"Heatwole C (2008) Mycophenolate mofetil for myasthenia gravis: a clear and present controversy. NDT. https:\/\/doi.org\/10.2147\/NDT.S3309","journal-title":"NDT"},{"key":"905_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368. https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"key":"905_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-2004-829585","volume":"24","author":"B Hughes","year":"2004","unstructured":"Hughes B, De Casillas M, Kaminski H (2004) Pathophysiology of myasthenia gravis. Semin Neurol 24:21\u201330. https:\/\/doi.org\/10.1055\/s-2004-829585","journal-title":"Semin Neurol"},{"key":"905_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mus.20440","volume":"33","author":"BW Hughes","year":"2006","unstructured":"Hughes BW, Kusner LL, Kaminski HJ (2006) Molecular architecture of the neuromuscular junction. Muscle Nerve 33:445\u2013461. https:\/\/doi.org\/10.1002\/mus.20440","journal-title":"Muscle Nerve"},{"key":"905_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/20009666.2018.1487245","volume":"8","author":"N Hussain","year":"2018","unstructured":"Hussain N, Hussain F, Haque D, Chittivelu S (2018) A diagnosis of late-onset myasthenia gravis unmasked by topical antibiotics. J Community Hosp Intern Med Perspect 8:230\u2013232. https:\/\/doi.org\/10.1080\/20009666.2018.1487245","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"905_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/096470490512580","volume":"14","author":"JD Johnston","year":"2005","unstructured":"Johnston JD (2005) Special section on myasthenia: the contributions of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in Poor Law Hospitals in London. J Hist Neurosci 14:121\u2013137. https:\/\/doi.org\/10.1080\/096470490512580","journal-title":"J Hist Neurosci"},{"key":"905_CR22","first-page":"10","volume":"43","author":"P Kornfeld","year":"1976","unstructured":"Kornfeld P, Horowitz SH, Genkins G, Papatestas AE (1976) Myasthenia gravis unmasked by antiarrhythmic agents. Mt Sinai J Med 43:10\u201314","journal-title":"Mt Sinai J Med"},{"key":"905_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26:1054\u20131054. https:\/\/doi.org\/10.1212\/WNL.26.11.1054","journal-title":"Neurology"},{"key":"905_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0022-510X(92)90165-H","volume":"109","author":"H Link","year":"1992","unstructured":"Link H, Sun J-B, Lu C-Z, Xiao B-G, Fredrikson S, H\u00f6jeberg B, Olson T (1992) Myasthenia gravis: T and B cell reactivities to the \u03b2-bungarotoxin binding protein presynaptic membrane receptor. J Neurol Sci 109:173\u2013181. https:\/\/doi.org\/10.1016\/0022-510X(92)90165-H","journal-title":"J Neurol Sci"},{"key":"905_CR25","doi-asserted-by":"publisher","first-page":"32195","DOI":"10.1073\/pnas.2022901117","volume":"117","author":"RP Lisak","year":"2020","unstructured":"Lisak RP, Richman DP (2020) Thymectomy and myasthenia gravis. Proc Natl Acad Sci USA 117:32195\u201332196. https:\/\/doi.org\/10.1073\/pnas.2022901117","journal-title":"Proc Natl Acad Sci USA"},{"key":"905_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006986.pub3","author":"MM Mehndiratta","year":"2014","unstructured":"Mehndiratta MM, Pandey S, Kuntzer T (2014) Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006986.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"905_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1365-2044.1995.tb06080.x","volume":"50","author":"A Mehta","year":"1995","unstructured":"Mehta A, Morris S (1995) Myasthenia gravis and sensitivity to muscle relaxants. Anaesthesia 50:574. https:\/\/doi.org\/10.1111\/j.1365-2044.1995.tb06080.x","journal-title":"Anaesthesia"},{"key":"905_CR102","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V (2020) Novel treatments in myasthenia gravis. Front Neurol 11:538. https:\/\/doi.org\/10.3389\/fneur.2020.00538","journal-title":"Front Neurol"},{"key":"905_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/01.phm.0000171169.79816.4c","volume":"84","author":"MN Meriggioli","year":"2005","unstructured":"Meriggioli MN, Sanders DB (2005) Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil 84:627\u2013638. https:\/\/doi.org\/10.1097\/01.phm.0000171169.79816.4c","journal-title":"Am J Phys Med Rehabil"},{"key":"905_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","volume":"48","author":"A Nacu","year":"2015","unstructured":"Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE (2015) Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 48:362\u2013368. https:\/\/doi.org\/10.3109\/08916934.2015.1030614","journal-title":"Autoimmunity"},{"issue":"6","key":"905_CR103","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/mus.880150616","volume":"15","author":"SJ Oh","year":"1992","unstructured":"Oh SJ et al (1992) Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 15(6):720\u2013724. https:\/\/doi.org\/10.1002\/mus.880150616","journal-title":"Muscle Nerve"},{"issue":"3","key":"905_CR105","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","volume":"58","author":"HJGH Oosterhuis","year":"1983","unstructured":"Oosterhuis HJGH et al (1983) Anti-acetylcholine receptor antibodies in myasthenia gravis. J Neurol Sci 58(3):371\u2013385. https:\/\/doi.org\/10.1016\/0022-510X(83)90096-5","journal-title":"J Neurol Sci"},{"key":"905_CR30","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B, Myasthenia Gravis Study Group (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50:1778\u20131783. https:\/\/doi.org\/10.1212\/WNL.50.6.1778","journal-title":"Neurology"},{"key":"905_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1749-6632.1998.tb10961.x","volume":"841","author":"AS Penn","year":"1998","unstructured":"Penn AS, Low BW, Jaffe IA, Luo L, Jacques JJ (1998) Drug-induced autoimmune myasthenia gravis. Ann N Y Acad Sci 841:433\u2013449. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb10961.x","journal-title":"Ann N Y Acad Sci"},{"key":"905_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2004-829593","volume":"24","author":"L Phillips","year":"2004","unstructured":"Phillips L (2004) The epidemiology of myasthenia gravis. Semin Neurol 24:17\u201320. https:\/\/doi.org\/10.1055\/s-2004-829593","journal-title":"Semin Neurol"},{"key":"905_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","volume":"107","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M (2005) Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 107:187\u2013190. https:\/\/doi.org\/10.1016\/j.clineuro.2004.07.013","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"905_CR106","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1212\/WNL.29.1.68","volume":"29","author":"DB Sanders","year":"1979","unstructured":"Sanders DB, Howard JF, Johns TR (1979) Single-fiber electromyography in myasthenia gravis. Neurology 29(1):68\u201368. https:\/\/doi.org\/10.1212\/WNL.29.1.68","journal-title":"Neurology"},{"key":"905_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4103\/0028-3886.43455","volume":"56","author":"B Singhal","year":"2008","unstructured":"Singhal B, Bhatia N, Umesh T, Menon S (2008) Myasthenia gravis: a study from India. Neurol India 56:352. https:\/\/doi.org\/10.4103\/0028-3886.43455","journal-title":"Neurol India"},{"issue":"2","key":"905_CR107","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0168-5597(93)90088-7","volume":"89","author":"FE Somnier","year":"1993","unstructured":"Somnier FE, Trojaborg W (1993) Neurophysiological evaluation in myasthenia gravis. A comprehensive study of a complete patient population. Electroencephalogr Clin Neurophysiol\/Evoked Potentials Sect 89(2):73\u201387. https:\/\/doi.org\/10.1016\/0168-5597(93)90088-7","journal-title":"Electroencephalogr Clin Neurophysiol\/Evoked Potentials Sect"},{"key":"905_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.crvi.2006.03.012","volume":"329","author":"EM Tansey","year":"2006","unstructured":"Tansey EM (2006) Henry Dale and the discovery of acetylcholine. CR Biol 329:419\u2013425. https:\/\/doi.org\/10.1016\/j.crvi.2006.03.012","journal-title":"CR Biol"},{"key":"905_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2474-5-42","volume":"5","author":"JF T\u00e9llez-Zenteno","year":"2004","unstructured":"T\u00e9llez-Zenteno JF, Hern\u00e1ndez-Ronquillo L, Salinas V, Estanol B, da Silva O (2004) Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. BMC Musculoskelet Disord 5:42. https:\/\/doi.org\/10.1186\/1471-2474-5-42","journal-title":"BMC Musculoskelet Disord"},{"key":"905_CR37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/pgmj.2004.018903","volume":"80","author":"BR Thanvi","year":"2004","unstructured":"Thanvi BR (2004) Update on myasthenia gravis. Postgrad Med J 80:690\u2013700. https:\/\/doi.org\/10.1136\/pgmj.2004.018903","journal-title":"Postgrad Med J"},{"key":"905_CR38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/pgmj.2004.018903","volume":"80","author":"BR Thanvi","year":"2004","unstructured":"Thanvi BR, Lo TCN (2004) Update on myasthenia gravis. Postgrad Med J 80:690. https:\/\/doi.org\/10.1136\/pgmj.2004.018903","journal-title":"Postgrad Med J"},{"key":"905_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RSA Tindall","year":"1987","unstructured":"Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719\u2013724. https:\/\/doi.org\/10.1056\/NEJM198703193161205","journal-title":"N Engl J Med"},{"key":"905_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RSA Tindall","year":"1993","unstructured":"Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K (1993) A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 681:539\u2013551. https:\/\/doi.org\/10.1111\/j.1749-6632.1993.tb22937.x","journal-title":"Ann NY Acad Sci"},{"key":"905_CR41","first-page":"1","volume-title":"Myasthenia gravis and related disorders","author":"EE Ubogu","year":"2009","unstructured":"Ubogu EE, Ruff RL (2009) Neuromuscular junction physiology and pathophysiology. Myasthenia gravis and related disorders. Humana Press, Totowa, pp 1\u201312"},{"key":"905_CR42","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A (2003) Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74:1105\u20131108. https:\/\/doi.org\/10.1136\/jnnp.74.8.1105","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"905_CR108","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","volume":"18","author":"A Vincent","year":"2005","unstructured":"Vincent A, Leite MI (2005) Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18(5):519\u2013525. https:\/\/doi.org\/10.1097\/01.wco.0000180660.57801.3f","journal-title":"Curr Opin Neurol"},{"key":"905_CR43","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D (2001) Myasthenia gravis. Lancet 357:2122\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(00)05186-2","journal-title":"Lancet"},{"key":"905_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-5728(83)90022-x","volume":"5","author":"PJ Whiting","year":"1983","unstructured":"Whiting PJ, Vincent A, Newsom-Davis J (1983) Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass. J Neuroimmunol 5:1\u20139. https:\/\/doi.org\/10.1016\/0165-5728(83)90022-x","journal-title":"J Neuroimmunol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-021-00905-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:29:14Z","timestamp":1646998154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-021-00905-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s10787-021-00905-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We, the authors, declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}